Article
FDA shoots down Mallinckrodt's redemption attempt, spurns rare kidney disease drug for a second tim
Rating:
0.0
Views:
238
Likes:
1
Library:
1
Whatever hope Mallinckrodt had following a narrow recommendation by the FDA advisory committee to approve terlipressin has been dashed by a firm rejection. The complete response letter stabbed right through the UK drugmaker's case for the drug, as regulators are asking for “more information to support a positive risk-benefit profile
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value